{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T17:38:32Z","timestamp":1792690712424,"version":"4.5.0"},"reference-count":138,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ymthe.2025.03.030","type":"journal-article","created":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T17:24:13Z","timestamp":1742664253000},"page":"2052-2064","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Recent developments in gene therapy for Parkinson\u2019s disease"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5199-7064","authenticated-orcid":false,"given":"Sandor","family":"Szunyogh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6691-580X","authenticated-orcid":false,"given":"Richard","family":"Wade-Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2025.03.030_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2021.776847","article-title":"Global Trends in the Incidence, Prevalence, and Years Lived With Disability of Parkinson's Disease in 204 Countries\/Territories From 1990 to 2019","volume":"9","author":"Ou","year":"2021","journal-title":"Front. Public Health"},{"key":"10.1016\/j.ymthe.2025.03.030_bib2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1001\/jamaneurol.2017.3299","article-title":"The Parkinson Pandemic-A Call to Action","volume":"75","author":"Dorsey","year":"2018","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ymthe.2025.03.030_bib3","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1474-4422(09)70068-7","article-title":"Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment","volume":"8","author":"Chaudhuri","year":"2009","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymthe.2025.03.030_bib4","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson's disease","volume":"386","author":"Kalia","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2025.03.030_bib5","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/S0140-6736(14)60683-8","article-title":"Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial","volume":"384","author":"Gray","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2025.03.030_bib6","first-page":"89","article-title":"Parkinson's disease: drug therapy","volume":"6","author":"Oertel","year":"1997","journal-title":"Baillieres Clin. Neurol."},{"key":"10.1016\/j.ymthe.2025.03.030_bib7","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1212\/WNL.26.4.305","article-title":"Mental symptoms in Parkinson's disease during chronic treatment with levodopa","volume":"26","author":"Sweet","year":"1976","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2025.03.030_bib8","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/mds.27602","article-title":"the collaborators of the Parkinson's Disease Update on Non-Motor Symptoms Study Group on behalf of the Movement Disorders Society Evidence-Based Medicine C. Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review","volume":"34","author":"Seppi","year":"2019","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ymthe.2025.03.030_bib9","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","article-title":"Viral vector platforms within the gene therapy landscape","volume":"6","author":"Bulcha","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ymthe.2025.03.030_bib10","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.030_bib11","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a008888","article-title":"Genetics of Parkinson's disease","volume":"2","author":"Klein","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.ymthe.2025.03.030_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/genes13081370","article-title":"Appraisal for the Potential of Viral and Nonviral Vectors in Gene Therapy: A Review","volume":"13","author":"Butt","year":"2022","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.ymthe.2025.03.030_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/gt.2016.71","article-title":"A brief account of viral vectors and their promise for gene therapy","volume":"24","author":"Finer","year":"2017","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.030_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/v15030698","article-title":"Viral Vectors in Gene Therapy: Where Do We Stand in 2023?","volume":"15","author":"Lundstrom","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.ymthe.2025.03.030_bib15","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/sj.gt.3302284","article-title":"Infectious delivery of the 132 kb CDKN2A\/CDKN2B genomic DNA region results in correctly spliced gene expression and growth suppression in glioma cells","volume":"11","author":"Inoue","year":"2004","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.030_bib16","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.omtm.2020.10.009","article-title":"Laboratory-Scale Lentiviral Vector Production and Purification for Enhanced Ex\u00a0Vivo and In\u00a0Vivo Genetic Engineering","volume":"19","author":"Soldi","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.03.030_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/cells12050785","article-title":"Various AAV Serotypes and Their Applications in Gene Therapy: An Overview","volume":"12","author":"Issa","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.ymthe.2025.03.030_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.crneur.2023.100086","article-title":"Advances in AAV technology for delivering genetically encoded cargo to the nonhuman primate nervous system","volume":"4","author":"Campos","year":"2023","journal-title":"Curr. Res. Neurobiol."},{"key":"10.1016\/j.ymthe.2025.03.030_bib19","article-title":"Non-replicative herpes simplex virus genomic and amplicon vectors for gene therapy - an update","author":"Le Hars","year":"2024","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.030_bib20","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41531-022-00321-y","article-title":"Mechanisms of peripheral levodopa resistance in Parkinson's disease","volume":"8","author":"Beckers","year":"2022","journal-title":"NPJ Parkinsons Dis."},{"key":"10.1016\/j.ymthe.2025.03.030_bib21","doi-asserted-by":"crossref","first-page":"10302","DOI":"10.1523\/JNEUROSCI.22-23-10302.2002","volume":"22","author":"Azzouz","year":"2002","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ymthe.2025.03.030_bib22","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1089\/hum.2004.15.1177","volume":"15","author":"Sun","year":"2004","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.030_bib23","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/S0140-6736(13)61939-X","article-title":"Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1\/2 trial","volume":"383","author":"Palfi","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2025.03.030_bib24","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1089\/humc.2018.081","article-title":"Long-Term Follow-Up of a Phase I\/II Study of ProSavin, a Lentiviral Vector Gene Therapy for Parkinson's Disease","volume":"29","author":"Palfi","year":"2018","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.03.030_bib25","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1089\/humc.2016.056","article-title":"Optimizing Transgene Configuration and Protein Fusions to Maximize Dopamine Production for the Gene Therapy of Parkinson's Disease","volume":"27","author":"Stewart","year":"2016","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.03.030_bib26","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.omtm.2019.07.002","article-title":"Gene Therapy for Parkinson's Disease: Preclinical Evaluation of Optimally Configured TH:CH1 Fusion for Maximal Dopamine Synthesis","volume":"14","author":"Badin","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.03.030_bib27","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/ana.25450","article-title":"Magnetic resonance imaging-guided phase 1 trial of putaminal AADC gene therapy for Parkinson's disease","volume":"85","author":"Christine","year":"2019","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymthe.2025.03.030_bib28","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/mds.27993","article-title":"Aromatic L-Amino Acid Decarboxylase Gene Therapy Enhances Levodopa Response in Parkinson's Disease","volume":"35","author":"Nutt","year":"2020","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ymthe.2025.03.030_bib29","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw1564","article-title":"Gene therapy restores dopamine transporter expression and ameliorates pathology in iPSC and mouse models of infantile parkinsonism","volume":"13","author":"Ng","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2025.03.030_bib30","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/s40001-024-01779-7","article-title":"Role of GABA pathway in motor and non-motor symptoms in Parkinson's disease: a bidirectional circuit","volume":"29","author":"Alharbi","year":"2024","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.ymthe.2025.03.030_bib31","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0306-4522(89)90120-6","article-title":"Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","volume":"32","author":"Mitchell","year":"1989","journal-title":"Neuroscience"},{"key":"10.1016\/j.ymthe.2025.03.030_bib32","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0166-2236(90)90110-V","article-title":"Primate models of movement disorders of basal ganglia origin","volume":"13","author":"DeLong","year":"1990","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.ymthe.2025.03.030_bib33","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1152\/jn.1994.72.2.507","article-title":"The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism","volume":"72","author":"Bergman","year":"1994","journal-title":"J.\u00a0Neurophysiol."},{"key":"10.1016\/j.ymthe.2025.03.030_bib34","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1523\/JNEUROSCI.17-02-00765.1997","article-title":"Consequences of nigrostriatal denervation on the functioning of the basal ganglia in human and nonhuman primates: an in\u00a0situ hybridization study of cytochrome oxidase subunit I mRNA","volume":"17","author":"Vila","year":"1997","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ymthe.2025.03.030_bib35","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/brain\/awh029","article-title":"The subthalamic nucleus in the context of movement disorders","volume":"127","author":"Hamani","year":"2004","journal-title":"Brain."},{"key":"10.1016\/j.ymthe.2025.03.030_bib36","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1093\/brain\/awh571","article-title":"Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up","volume":"128","author":"Rodriguez-Oroz","year":"2005","journal-title":"Brain."},{"key":"10.1016\/j.ymthe.2025.03.030_bib37","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1126\/science.1074549","article-title":"Subthalamic GAD gene therapy in a Parkinson's disease rat model","volume":"298","author":"Luo","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.03.030_bib38","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/sj.jcbfm.9600364","article-title":"Subthalamic glutamic acid decarboxylase gene therapy: changes in motor function and cortical metabolism","volume":"27","author":"Emborg","year":"2007","journal-title":"J.\u00a0Cereb. Blood Flow Metab."},{"key":"10.1016\/j.ymthe.2025.03.030_bib39","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1038\/sj.gt.3302520","article-title":"Enhanced expression of glutamate decarboxylase 65 improves symptoms of rat parkinsonian models","volume":"12","author":"Lee","year":"2005","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.030_bib40","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1016\/S0140-6736(07)60982-9","article-title":"Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial","volume":"369","author":"Kaplitt","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2025.03.030_bib41","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S1474-4422(11)70039-4","article-title":"AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial","volume":"10","author":"LeWitt","year":"2011","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymthe.2025.03.030_bib42","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1177\/1756285609339382","article-title":"Deep brain stimulation in Parkinson's disease","volume":"2","author":"Groiss","year":"2009","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.ymthe.2025.03.030_bib43","series-title":"MeiraGTx Announces Positive Data from Randomized, Sham-controlled Clinical Bridging Study of AAV-GAD for the Treatment of Parkinson\u2019s Disease. MeiraGTx Press release","author":"MeiraGTx","year":"2024"},{"key":"10.1016\/j.ymthe.2025.03.030_bib44","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/ejn.14102","article-title":"Trophic factors for Parkinson's disease: Where are we and where do we go from here?","volume":"49","author":"Paul","year":"2019","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.ymthe.2025.03.030_bib45","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.3233\/JPD-212706","article-title":"GDNF Therapy: Can We Make It Work?","volume":"11","author":"Bjorklund","year":"2021","journal-title":"J.\u00a0Parkinsons Dis."},{"key":"10.1016\/j.ymthe.2025.03.030_bib46","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.pneurobio.2005.09.001","article-title":"The role of Nurr1 in the development of dopaminergic neurons and Parkinson's disease","volume":"77","author":"Jankovic","year":"2005","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.ymthe.2025.03.030_bib47","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1093\/brain\/awz023","article-title":"Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson's disease","volume":"142","author":"Whone","year":"2019","journal-title":"Brain."},{"key":"10.1016\/j.ymthe.2025.03.030_bib48","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1002\/mds.29820","article-title":"Persistent GDNF Expression 45 Months after Putaminal Infusion of AAV2-GDNF in a Patient with Parkinson's Disease","volume":"39","author":"Heiss","year":"2024","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ymthe.2025.03.030_bib49","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/sj.mt.6300010","article-title":"Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease","volume":"15","author":"Gasmi","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.030_bib50","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S1474-4422(08)70065-6","article-title":"Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial","volume":"7","author":"Marks","year":"2008","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymthe.2025.03.030_bib51","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/ana.24436","article-title":"Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial","volume":"78","author":"Warren Olanow","year":"2015","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymthe.2025.03.030_bib52","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1089\/hum.2015.134","article-title":"Long-Term Safety of Patients with Parkinson's Disease Receiving rAAV2-Neurturin (CERE-120) Gene Transfer","volume":"27","author":"Marks","year":"2016","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.030_bib53","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1093\/brain\/awaa020","article-title":"Long-term post-mortem studies following neurturin gene therapy in patients with advanced Parkinson's disease","volume":"143","author":"Chu","year":"2020","journal-title":"Brain."},{"key":"10.1016\/j.ymthe.2025.03.030_bib54","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2023.1188697","article-title":"CDNF and MANF in the brain dopamine system and their potential as treatment for Parkinson's disease","volume":"14","author":"Pakarinen","year":"2023","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.ymthe.2025.03.030_bib55","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nature05957","article-title":"Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in\u00a0vivo","volume":"448","author":"Lindholm","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.03.030_bib56","doi-asserted-by":"crossref","first-page":"9651","DOI":"10.1523\/JNEUROSCI.0833-09.2009","article-title":"Mesencephalic astrocyte-derived neurotrophic factor is neurorestorative in rat model of Parkinson's disease","volume":"29","author":"Voutilainen","year":"2009","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ymthe.2025.03.030_bib57","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1002\/mds.29426","article-title":"Intraputamenal Cerebral Dopamine Neurotrophic Factor in Parkinson's Disease: A Randomized, Double-Blind, Multicenter Phase 1 Trial","volume":"38","author":"Huttunen","year":"2023","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ymthe.2025.03.030_bib58","article-title":"Therapeutic efficacy of AAV8-mediated intrastriatal delivery of human cerebral dopamine neurotrophic factor in 6-OHDA-induced parkinsonian rat models with different disease progression","volume":"12","author":"Wang","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2025.03.030_bib59","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.expneurol.2013.06.002","article-title":"AAV2-mediated striatum delivery of human CDNF prevents the deterioration of midbrain dopamine neurons in a 6-hydroxydopamine induced parkinsonian rat model","volume":"248","author":"Ren","year":"2013","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ymthe.2025.03.030_bib60","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/brb3.117","article-title":"Gene therapy with AAV2-CDNF provides functional benefits in a rat model of Parkinson's disease","volume":"3","author":"Back","year":"2013","journal-title":"Brain Behav."},{"key":"10.1016\/j.ymthe.2025.03.030_bib61","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/mt.2014.206","article-title":"Enhanced efficacy of the CDNF\/MANF family by combined intranigral overexpression in the 6-OHDA rat model of Parkinson's disease","volume":"23","author":"Cordero-Llana","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.030_bib62","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-65735-5","article-title":"Delivery of CDNF by AAV-mediated gene transfer protects dopamine neurons and regulates ER stress and inflammation in an acute MPTP mouse model of Parkinson's disease","volume":"14","author":"Nam","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2025.03.030_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.biocel.2022.106187","article-title":"Platelet-derived growth factor signalling in neurovascular function and disease","volume":"145","author":"Li","year":"2022","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.ymthe.2025.03.030_bib64","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/BF00242187","article-title":"Specific effects of platelet derived growth factor (PDGF) on fetal rat and human dopaminergic neurons in\u00a0vitro","volume":"105","author":"Othberg","year":"1995","journal-title":"Exp. Brain Res."},{"key":"10.1016\/j.ymthe.2025.03.030_bib65","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0304-3940(96)12326-0","article-title":"Protective effect of platelet-derived growth factor against 6-hydroxydopamine-induced lesion of rat dopaminergic neurons in culture","volume":"204","author":"Pietz","year":"1996","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ymthe.2025.03.030_bib66","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1172\/JCI79635","article-title":"Safety and tolerability of intracerebroventricular PDGF-BB in Parkinson's disease patients","volume":"125","author":"Paul","year":"2015","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.03.030_bib67","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.nbd.2016.03.026","article-title":"Clinical tests of neurotrophic factors for human neurodegenerative diseases, part 2: Where do we stand and where must we go next?","volume":"97","author":"Bartus","year":"2017","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ymthe.2025.03.030_bib68","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1038\/s41556-024-01513-9","article-title":"The role of PINK1-Parkin in mitochondrial quality control","volume":"26","author":"Narendra","year":"2024","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.ymthe.2025.03.030_bib69","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrc.2017.52","article-title":"Fragile sites in cancer: more than meets the eye","volume":"17","author":"Glover","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ymthe.2025.03.030_bib70","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.695172","article-title":"Large Intronic Deletion of the Fragile Site Gene PRKN Dramatically Lowers Its Fragility Without Impacting Gene Expression","volume":"12","author":"Munk","year":"2021","journal-title":"Front. Genet."},{"key":"10.1016\/j.ymthe.2025.03.030_bib71","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1074\/jbc.M510393200","article-title":"Diverse effects of pathogenic mutations of Parkin that catalyze multiple monoubiquitylation in\u00a0vitro","volume":"281","author":"Matsuda","year":"2006","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2025.03.030_bib72","doi-asserted-by":"crossref","first-page":"47199","DOI":"10.1074\/jbc.M306769200","article-title":"Inactivation of parkin by oxidative stress and C-terminal truncations: a protective role of molecular chaperones","volume":"278","author":"Winklhofer","year":"2003","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2025.03.030_bib73","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1152\/physrev.00022.2010","article-title":"What genetics tells us about the causes and mechanisms of Parkinson's disease","volume":"91","author":"Corti","year":"2011","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ymthe.2025.03.030_bib74","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1056\/NEJM200005253422103","article-title":"Association between early-onset Parkinson's disease and mutations in the parkin gene","volume":"342","author":"Lucking","year":"2000","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.030_bib75","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1212\/01.wnl.0000327098.86861.d4","article-title":"A multidisciplinary study of patients with early-onset PD with and without parkin mutations","volume":"72","author":"Lohmann","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2025.03.030_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107326","article-title":"a therapeutic gene delivery cargo, enhances motor and cognitive functions in Parkinson's and Alzheimer's diseases","volume":"208","author":"Lee","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ymthe.2025.03.030_bib77","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/humu.21277","article-title":"Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update","volume":"31","author":"Nuytemans","year":"2010","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ymthe.2025.03.030_bib78","doi-asserted-by":"crossref","first-page":"5703","DOI":"10.1073\/pnas.0500617102","article-title":"Mutations in PTEN-induced putative kinase 1 associated with recessive parkinsonism have differential effects on protein stability","volume":"102","author":"Beilina","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.03.030_bib79","doi-asserted-by":"crossref","first-page":"34025","DOI":"10.1074\/jbc.M505143200","article-title":"Wild-type PINK1 prevents basal and induced neuronal apoptosis, a protective effect abrogated by Parkinson disease-related mutations","volume":"280","author":"Petit","year":"2005","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2025.03.030_bib80","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1038\/emboj.2010.223","article-title":"Inhibition of mitochondrial fusion by alpha-synuclein is rescued by PINK1, Parkin and DJ-1","volume":"29","author":"Kamp","year":"2010","journal-title":"EMBO J."},{"key":"10.1016\/j.ymthe.2025.03.030_bib81","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1016\/j.neurobiolaging.2014.04.032","article-title":"Alpha-synuclein-induced neurodegeneration is exacerbated in PINK1 knockout mice","volume":"35","author":"Oliveras-Salva","year":"2014","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.ymthe.2025.03.030_bib82","article-title":"Defective PTEN-induced kinase 1\/Parkin mediated mitophagy and neurodegenerative diseases","volume":"16","author":"Braun","year":"2022","journal-title":"Front. Cel. Neurosci."},{"key":"10.1016\/j.ymthe.2025.03.030_bib83","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2014.581","article-title":"PINK1-induced mitophagy promotes neuroprotection in Huntington's disease","volume":"6","author":"Khalil","year":"2015","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ymthe.2025.03.030_bib84","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1093\/brain\/awx258","article-title":"PINK1 signalling rescues amyloid pathology and mitochondrial dysfunction in Alzheimer's disease","volume":"140","author":"Du","year":"2017","journal-title":"Brain."},{"key":"10.1016\/j.ymthe.2025.03.030_bib85","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3389\/fneur.2013.00038","article-title":"Structure and Function of Parkin, PINK1, and DJ-1, the Three Musketeers of Neuroprotection","volume":"4","author":"Trempe","year":"2013","journal-title":"Front. Neurol."},{"key":"10.1016\/j.ymthe.2025.03.030_bib86","article-title":"DJ-1 in Parkinson's Disease: Clinical Insights and Therapeutic Perspectives","volume":"8","author":"Repici","year":"2019","journal-title":"J.\u00a0Clin. Med."},{"key":"10.1016\/j.ymthe.2025.03.030_bib87","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.0020362","article-title":"DJ-1 is a redox-dependent molecular chaperone that inhibits alpha-synuclein aggregate formation","volume":"2","author":"Shendelman","year":"2004","journal-title":"Plos Biol."},{"key":"10.1016\/j.ymthe.2025.03.030_bib88","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jphs.2015.01.010","article-title":"DJ-1-dependent protective activity of DJ-1-binding compound no. 23 against neuronal cell death in MPTP-treated mouse model of Parkinson's disease","volume":"127","author":"Takahashi-Niki","year":"2015","journal-title":"J.\u00a0Pharmacol. Sci."},{"key":"10.1016\/j.ymthe.2025.03.030_bib89","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1038\/sj.mt.6300154","article-title":"DJ-1 and Parkin modulate dopamine-dependent behavior and inhibit MPTP-induced nigral dopamine neuron loss in mice","volume":"15","author":"Paterna","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.030_bib90","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.tins.2019.10.002","article-title":"Lysosomal Dysfunction at the Centre of Parkinson's Disease and Frontotemporal Dementia\/Amyotrophic Lateral Sclerosis","volume":"42","author":"Wallings","year":"2019","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.ymthe.2025.03.030_bib91","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1093\/brain\/awx285","article-title":"Excessive burden of lysosomal storage disorder gene variants in Parkinson's disease","volume":"140","author":"Robak","year":"2017","journal-title":"Brain."},{"key":"10.1016\/j.ymthe.2025.03.030_bib92","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/hmg\/ddq454","article-title":"Large-scale screening of the Gaucher's disease-related glucocerebrosidase gene in Europeans with Parkinson's disease","volume":"20","author":"Lesage","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2025.03.030_bib93","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/jnc.13385","article-title":"The relationship between glucocerebrosidase mutations and Parkinson disease","author":"Migdalska-Richards","year":"2016","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.ymthe.2025.03.030_bib94","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","article-title":"Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease","volume":"361","author":"Sidransky","year":"2009","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.030_bib95","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1136\/jnnp.48.2.172","article-title":"Neurological involvement in type 1 (adult) Gaucher's disease","volume":"48","author":"McKeran","year":"1985","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.ymthe.2025.03.030_bib96","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13024-019-0336-2","article-title":"Glucocerebrosidase and its relevance to Parkinson disease","volume":"14","author":"Do","year":"2019","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.ymthe.2025.03.030_bib97","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","article-title":"Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease","volume":"324","author":"Barton","year":"1991","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.030_bib98","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1007\/s10545-009-1164-2","article-title":"Management of neuronopathic Gaucher disease: revised recommendations","volume":"32","author":"Vellodi","year":"2009","journal-title":"J.\u00a0Inherit. Metab. Dis."},{"key":"10.1016\/j.ymthe.2025.03.030_bib99","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/s41591-018-0106-7","article-title":"Fetal gene therapy for neurodegenerative disease of infants","volume":"24","author":"Massaro","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.03.030_bib100","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1016\/j.ymthe.2017.08.004","article-title":"AAV-PHP.B-Mediated Global-Scale Expression in the Mouse Nervous System Enables GBA1 Gene Therapy for Wide Protection from Synucleinopathy","volume":"25","author":"Morabito","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.030_bib101","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.nbd.2015.09.009","article-title":"Glucocerebrosidase gene therapy prevents alpha-synucleinopathy of midbrain dopamine neurons","volume":"82","author":"Rocha","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ymthe.2025.03.030_bib102","first-page":"2645","article-title":"Glucocerebrosidase modulates cognitive and motor activities in murine models of Parkinson's disease","volume":"25","author":"Rockenstein","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2025.03.030_bib103","doi-asserted-by":"crossref","first-page":"12101","DOI":"10.1073\/pnas.1108197108","article-title":"CNS expression of glucocerebrosidase corrects alpha-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy","volume":"108","author":"Sardi","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.03.030_bib104","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nbt.1515","article-title":"Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes","volume":"27","author":"Foust","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.03.030_bib105","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1096\/fj.11-182311","article-title":"Intravenous administration of AAV2\/9 to the fetal and neonatal mouse leads to differential targeting of CNS cell types and extensive transduction of the nervous system","volume":"25","author":"Rahim","year":"2011","journal-title":"FASEB J."},{"key":"10.1016\/j.ymthe.2025.03.030_bib106","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nbt.3440","article-title":"Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain","volume":"34","author":"Deverman","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.03.030_bib107","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.stemcr.2016.01.013","article-title":"ER Stress and Autophagic Perturbations Lead to Elevated Extracellular alpha-Synuclein in GBA-N370S Parkinson's iPSC-Derived Dopamine Neurons","volume":"6","author":"Fernandes","year":"2016","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.ymthe.2025.03.030_bib108","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1474-4422(12)70190-4","article-title":"The link between the GBA gene and parkinsonism","volume":"11","author":"Sidransky","year":"2012","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymthe.2025.03.030_bib109","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41531-022-00397-6","article-title":"Lysosomal lipid alterations caused by glucocerebrosidase deficiency promote lysosomal dysfunction, chaperone-mediated-autophagy deficiency, and alpha-synuclein pathology","volume":"8","author":"Navarro-Romero","year":"2022","journal-title":"NPJ Parkinsons Dis."},{"key":"10.1016\/j.ymthe.2025.03.030_bib110","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1093\/hmg\/ddi240","article-title":"ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity","volume":"14","author":"Ron","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2025.03.030_bib111","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abm6393","article-title":"Mutant glucocerebrosidase impairs alpha-synuclein degradation by blockade of chaperone-mediated autophagy","volume":"8","author":"Kuo","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ymthe.2025.03.030_bib112","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuint.2012.10.010","article-title":"Glucocerebrosidase inhibition causes mitochondrial dysfunction and free radical damage","volume":"62","author":"Cleeter","year":"2013","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.ymthe.2025.03.030_bib113","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.neuro.2009.06.009","article-title":"Alpha-synuclein-glucocerebrosidase interactions in pharmacological Gaucher models: a biological link between Gaucher disease and parkinsonism","volume":"30","author":"Manning-Bog","year":"2009","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.ymthe.2025.03.030_bib114","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cell.2011.06.001","article-title":"Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies","volume":"146","author":"Mazzulli","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2025.03.030_bib115","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","article-title":"Mutation in the alpha-synuclein gene identified in families with Parkinson's disease","volume":"276","author":"Polymeropoulos","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.03.030_bib116","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S0140-6736(04)17103-1","article-title":"Alpha-synuclein locus duplication as a cause of familial Parkinson's disease","volume":"364","author":"Chartier-Harlin","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2025.03.030_bib117","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1126\/science.1090278","article-title":"alpha-Synuclein locus triplication causes Parkinson's disease","volume":"302","author":"Singleton","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.03.030_bib118","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1212\/01.WNL.0000127517.33208.F4","article-title":"Alpha-synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication","volume":"62","author":"Miller","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2025.03.030_bib119","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1212\/01.wnl.0000254458.17630.c5","article-title":"Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication","volume":"68","author":"Fuchs","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2025.03.030_bib120","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.brainres.2011.04.036","article-title":"An alpha-synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson's disease, but displays toxicity in dopamine neurons","volume":"1395","author":"Khodr","year":"2011","journal-title":"Brain Res."},{"key":"10.1016\/j.ymthe.2025.03.030_bib121","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.expneurol.2005.12.024","article-title":"Silencing of human alpha-synuclein in\u00a0vitro and in rat brain using lentiviral-mediated RNAi","volume":"198","author":"Sapru","year":"2006","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ymthe.2025.03.030_bib122","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1172\/JCI64502","article-title":"shRNA targeting alpha-synuclein prevents neurodegeneration in a Parkinson's disease model","volume":"125","author":"Zharikov","year":"2015","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.03.030_bib123","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcab247","article-title":"Viral alpha-synuclein knockdown prevents spreading synucleinopathy","volume":"3","author":"Menon","year":"2021","journal-title":"Brain Commun."},{"key":"10.1016\/j.ymthe.2025.03.030_bib124","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1016\/j.ymthe.2018.08.019","article-title":"Downregulation of SNCA Expression by Targeted Editing of DNA Methylation: A Potential Strategy for Precision Therapy in PD","volume":"26","author":"Kantor","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.030_bib125","series-title":"SNCA Gene Repression Mediated by Zinc Finger Repressors (ZFRs) as a Therapeutic Approach for Parkinson\u2019s Disease","author":"Young","year":"2024"},{"key":"10.1016\/j.ymthe.2025.03.030_bib126","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.brainres.2014.01.010","article-title":"Targeting alpha-synuclein with a microRNA-embedded silencing vector in the rat substantia nigra: positive and negative effects","volume":"1550","author":"Khodr","year":"2014","journal-title":"Brain Res."},{"key":"10.1016\/j.ymthe.2025.03.030_bib127","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3389\/fnmol.2018.00036","article-title":"Silencing Alpha Synuclein in Mature Nigral Neurons Results in Rapid Neuroinflammation and Subsequent Toxicity","volume":"11","author":"Benskey","year":"2018","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.ymthe.2025.03.030_bib128","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1038\/mt.2010.115","article-title":"In\u00a0vivo RNAi-mediated alpha-synuclein silencing induces nigrostriatal degeneration","volume":"18","author":"Gorbatyuk","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.030_bib129","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.nbd.2019.01.004","article-title":"Long-term RNAi knockdown of alpha-synuclein in the adult rat substantia nigra without neurodegeneration","volume":"125","author":"Zharikov","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ymthe.2025.03.030_bib130","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/sj.gt.3301905","article-title":"Human synapsin 1 gene promoter confers highly neuron-specific long-term transgene expression from an adenoviral vector in the adult rat brain depending on the transduced area","volume":"10","author":"Kugler","year":"2003","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.030_bib131","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.gene.2008.09.033","article-title":"Epigenetic regulation of cytomegalovirus major immediate-early promoter activity in transgenic mice","volume":"428","author":"Mehta","year":"2009","journal-title":"Gene"},{"key":"10.1016\/j.ymthe.2025.03.030_bib132","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1038\/mt.2009.64","article-title":"Physiological transgene regulation and functional complementation of a neurological disease gene deficiency in neurons","volume":"17","author":"Peruzzi","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.030_bib133","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nbt1101-1067","article-title":"An infectious transfer and expression system for genomic DNA loci in human and mouse cells","volume":"19","author":"Wade-Martins","year":"2001","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.03.030_bib134","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/sj.mt.6300021","article-title":"Infectious Delivery and Expression of a 135 kb Human FRDA Genomic DNA Locus Complements Friedreich's Ataxia Deficiency in Human Cells","volume":"15","author":"Gomez-Sebastian","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.030_bib135","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/gt.2011.45","article-title":"Infectious delivery and long-term persistence of transgene expression in the brain by a 135-kb iBAC-FXN genomic DNA expression vector","volume":"18","author":"Gimenez-Cassina","year":"2011","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.030_bib136","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/nm.2199","article-title":"Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease","volume":"16","author":"Lee","year":"2010","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.03.030_bib137","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2023.1172197","article-title":"Common mechanisms underlying axonal transport deficits in neurodegenerative diseases: a mini review","volume":"16","author":"Yang","year":"2023","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.ymthe.2025.03.030_bib138","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/s41582-019-0257-2","article-title":"Axonal transport and neurological disease","volume":"15","author":"Sleigh","year":"2019","journal-title":"Nat. Rev. Neurol."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625002047?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625002047?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:40:18Z","timestamp":1792687218000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001625002047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":138,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1525001625002047"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.03.030","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent developments in gene therapy for Parkinson\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.03.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}